

**SAMORITA HOSPITAL LIMITED**  
**First Quarter Financial Statements**

Dear Shareholders,

We are pleased to forward herewith the unaudited Financial Statements of the company for the first quarter ended 30th September, 2022 as per Bangladesh Securities and Exchange Commission's notification No. SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009.

**Statement of Financial Position (Un-audited)**  
**As at 30 September, 2022 (Figure in Taka "000")**

Particular	Notes	September,30 2022	June, 30 2022
<b>Assets</b>			
<b>Non-Current Assets</b>			
Property, Plant & Equipment(WDV)	3	984,641	978,120
Right of Use Assets	4	3,593	3,992
Investment in Associate	5	5,844	5,829
<b>Total Non-Current Assets</b>		<b>994,078</b>	<b>987,941</b>
<b>Current Assets:</b>			
Inventories	6	20,380	20,411
Trade Receivable	7	10,550	10,322
Advance,Deposits & Prepayments	8	19,222	18,251
Advance Income Tax	9	15,902	15,787
Cash & Cash Equivalents	10	68,240	69,462
<b>Total Current Assets</b>		<b>134,294</b>	<b>134,233</b>
<b>Total Assets</b>		<b>1,128,372</b>	<b>1,122,174</b>
<b>Equity and Liabilities</b>			
<b>Shareholders' Equity:</b>			
Share Capital	11	188,752	188,752
Retained Earnings	12	142,945	140,203
Revaluation Reserve	14	636,826	636,826
Dividend Equalisation Fund	13	2,919	2,919
<b>Total Equity</b>		<b>971,442</b>	<b>968,700</b>
<b>Non- Current Liabilities :</b>			
Deferred Tax Liabilities	15	43,364	43,323
Lease Liability	16.01	2,264	2,264
Long Term Loan	17	35,491	35,491
<b>Total Non- Current Liabilities</b>		<b>81,119</b>	<b>81,078</b>
<b>Current Liabilities :</b>			
Trade Payable	18	33,573	30,728
Long Term Loan (Current Portion)	19	17,028	21,060
Lease Liability- current portion	16.01	1,447	1,815
Other Payable	20	2,882	744
Provision & Accruals	21	10,011	9,021
Provision for Income Taxes	22	8,771	7,856
Unclaimed Dividend	23	2,100	1,172
<b>Total Current Liabilities</b>		<b>75,811</b>	<b>72,396</b>
<b>Total Liabilities</b>		<b>156,930</b>	<b>153,474</b>
<b>Total Equity and Liabilities</b>		<b>1,128,372</b>	<b>1,122,174</b>

**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
**For the first quarter ended 30th September, 2022. (Figure in Taka "000")**

	Notes	July, 2022 to September, 2022	July, 2021 to September, 2021
Revenue	25	82,931	119,930
Direct Expenses	26	(33,643)	(47,355)
<b>Gross Profit</b>		<b>49,288</b>	<b>72,575</b>
<b>Operating Expenses:</b>			
Administrative Expenses	27	(46,046)	(45,157)
<b>Profit from Operation</b>		<b>3,242</b>	<b>27,418</b>
Share of Profit/ (loss) of Associate	24	15	28
Financial Expenses	28	(1,319)	(1,300)
Non Operating Income	29	1,945	1,474
<b>Profit before contribution to WPPF</b>		<b>3,883</b>	<b>27,620</b>
Contribution to WPPF		(185)	(1,315)
<b>Profit Before Tax</b>		<b>3,697</b>	<b>26,305</b>
<b>Income Tax Expenses</b>		<b>(955)</b>	<b>(5,913)</b>
Current Tax	30	915	6,276
Deferred Tax	15.01	40	(364)
<b>Profit after Tax</b>		<b>2,742</b>	<b>20,392</b>
<b>Total Comprehensive income</b>		<b>2,742</b>	<b>20,392</b>
<b>EPS</b>		<b>0.15</b>	<b>1.08</b>

  
CFO

  
Company Secretary

  
Managing Director

  
Director

  
Chairman

**Statement of Changes In Equity (Un-audited)**  
For the first quarter ended 30th September, 2022. (Figure in Taka "000")

Particular	Share Capital	Retained Earning	Dividend Equalisation Fund	Revaluation Reserve	Total
Balance as at July 01,2022	188,752	140,203	2,919	636,826	968,700
Transferred to Dividend Equalisation Fund	-	-	-	-	-
Total Comprehensive income	-	2,742	-	-	2,742
<b>Balance as at September 30,2022</b>	<b>188,752</b>	<b>142,945</b>	<b>2,919</b>	<b>636,826</b>	<b>971,442</b>
Balance as at July 01,2021	188,752	145,705	-	636,826	971,283
Transferred to Dividend Equalisation Fund	-	(2,104)	2,104	-	-
Total Comprehensive income	-	20,392	-	-	20,392
<b>Balance as at September 30,2021</b>	<b>188,752</b>	<b>163,993</b>	<b>2,104</b>	<b>636,826</b>	<b>991,675</b>

**Statement of Cash Flows (Un-audited)**  
For the first quarter ended 30th September, 2022. (Figure in Taka"000")

	September,30 2022	September,30 2021
<b>A. Cash flows from Operating Activities:</b>		
Cash Received from Customers	86,191	116,506
Cash Paid to Suppliers & Employees	(68,610)	(84,301)
<b>Cash generated from Operations:</b>	<b>17,581</b>	<b>32,205</b>
Income Tax Paid	(115)	(2,616)
<b>Net Cash from Operating Activities</b>	<b>17,466</b>	<b>29,589</b>
<b>B. Cash flows from Investing Activities</b>		
Purchase of Property, Plant & Equipment	(14,876)	(8,047)
FDR interest	525	700
<b>Net Cash used in Investing Activities</b>	<b>(14,351)</b>	<b>(7,347)</b>
<b>C. Cash flows from Financing Activities</b>		
Bank Loan paid	(5,265)	-
Unclaimed Dividend	928	(8,166)
<b>Net Cash Used in Financing Activities</b>	<b>(4,337)</b>	<b>(8,166)</b>
<b>D. Net Cash Inflows / (outflows)</b>	<b>(1,222)</b>	<b>14,076</b>
<b>E. Opening Cash &amp; Bank Balance</b>	<b>69,462</b>	<b>67,308</b>
<b>F. Closing Cash &amp; Bank Balance</b>	<b>68,240</b>	<b>81,384</b>

**Additional information as per listing regulation:**

Particulars	September,30 2022	June,30 2022
Net Assets Value per Share (NAV)	51.47	51.32
Earning Per Share(EPS)	0.15	1.08
Net Operating Cash Flow Per Share(NOCFPS)	0.93	1.57

**Reasons of deviation in financial parameters:**

**Operating results:**

Operating result in the reporting period has been significantly decreased due to the following reasons, compared to previous corresponding period:


- Revenue has been decreased by Tk. 3.70 Crore.
- Cost of direct materials has been increased by 1.08%.
- Administrative expenses has been increased from 37.65% to 55.52% of revenue.

Net operating cash flow per share (NOCFPS) decreased from Tk. 1.57 to Tk.0.93 due to Cash receipts from Customers have been decreased by Tk. 3.03 Crore.

  
CFO

  
Company Secretary

  
Managing Director

  
Director

  
Chairman

"The details of the published first quarter financial statements can be available in the web-site of the company. The address of the web-site is [www.samoritahospital.org](http://www.samoritahospital.org) "



**1.00 Legal status and nature of the Company-Disclosure under IAS-1 "Presentation of Financial Statements".**  
**1.01 Company Profile**

Samorita Hospital Limited started its business from 01 February 1984 under the name and style as "M/s. Samorita Nursing Home". Then it was a partnership concern and 14 October 1985 it was converted into a Private Limited Company under the name and style as Samorita Nursing Home Ltd. Subsequently its name and style was changed and renamed as Samorita Hospital (Pvt.) Limited on 17 January 1990. Again on 23 June 1996 it was converted into a Public Limited Company under the name and style as "Samorita Hospital Limited".

The company went for public issue of share in 1996 and its shares are listed with the Stock Exchanges of Bangladesh.

**1.02 Basis of preparation of Financial Statements:**

These interim Financial Statements should be read in conjunction with the financial statements for the year ended 30th June, 2022 as they provide an update to previously reported information.

The Accounting Policies used are consistent with those in the Annual Financial Statements. The Financial Statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRS). The Presentation of the interim Financial Statements is consistent with the Annual Financial Statements.

**1.03 Investment in associate Company:**

The Company's investment in associate company is accounted for in the financial statements using the Equity Method in accordance with IAS-28 "Investment in Associates".

**2.00 Specific Accounting Policies selected and applied for Significant Transactions and Events:**  
**2.01 Accounting Convention (Measurement IASs)**

The financial statements have been prepared on a going concern basis under the historical cost convention in accordance with International Financial Reporting Standards (IFRSs) therefore, do not take into consideration the effect of inflation.

**2.02 Statement of compliance**

The financial statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRSs), and The Companies Act 1994 and Securities & Exchange Rules 1987.

**2.03 Reporting Currency and Level of Precision**

The financial statements are presented in Bangladeshi Taka (BDT) which is the functional currency of the company. The amounts in these financial statements have been rounded off to the nearest integer.

**2.04 Risk and Uncertainties for use of estimates in preparation of Financial Statements**

The preparation of Financial Statements in conformity with the International Financial Reporting Standards requires management to make estimates and assumptions that affects the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. Actual result could differ from those estimates. Estimates are used for accounting certain items such as long term contract, provision for doubtful contracts, depreciation and amortization, Tax reserve and contingencies.

**2.05 Reporting Period**

The company's accounting year is July-June and this financial statements are prepared covering the period of three month from 01 July 2022 to 30 September 2022.

**2.06 Comparative Information**

Comparative information has been disclosed in respect of the period in accordance with IAS-1: Presentation of Financial Statements, for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period's financial statements.

**2.07 Recognition of Property, Plant & Equipment and Depreciation**

Property, plant & equipment are recognized if it is probable that future economic benefits associated with the assets will flow to the company and the cost of the assets can be reliably measured. All fixed assets are stated at cost or revaluation less accumulated depreciation as per IAS-16 "Property, Plant and Equipment". No depreciation is charged on land and land development. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes. The cost and accumulated depreciation of depreciable assets retired or otherwise disposed of are subject to elimination from the assets and accumulated depreciation and any gain or loss on such disposal will reflect in operations for the period.

**2.08 Inventories**

Inventories comprise various Medicine, Material for Pathology, X-Ray, OT, Cleaning Materials, Linens, Printing and Stationery, Materials for ECG and USG. They are stated at the lower of cost and net realizable value in accordance with IAS -2 "Inventories" after making due allowances for any obsolete or slow moving items.



## 2.09 Financial Instruments

### Financial Assets

#### Trade Receivable

Trade receivables are recognized and stated at original invoiced amounts and carried at anticipated realizable values.

#### Cash and Cash Equivalent

It includes cash in hand and cash at bank which were held and available for use by the company without any restriction and there was insignificant risk of change in value of these current assets.

## 2.10 Creditors and Accrued Expenses

Liabilities are recognized for amounts to be paid in future for goods and services received, whether or not billed by the supplier.

## 2.11 Taxation

Income tax expenses comprise current and deferred taxes. Income taxes are recognized in statement of profit or loss and other comprehensive income except to the extent that relates to items recognized directly in equity or in other comprehensive income. The Company is a publicly traded Company. As per the Income Tax Ordinance, 1984, provision for Tax has been made at the existing rate of 22.50% in respect of business income.

### Current Tax

Provision for current income tax has been made as per prescribed rate in the Finance Act, 2022 on the accounting profit made by the company after considering some of the add backs to income and disallowances of expenditure as per income tax laws in compliance with IAS-12: "Income Taxes".

### Deferred Tax

Deferred tax liabilities are the amount of income taxes payable in future periods in respect of taxable temporary differences. Deferred tax assets are the amount of income taxes recoverable in future periods in respect of deductible temporary differences. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences arising between the carrying values of assets, liabilities, income and expenditure and their respective tax bases. Deferred tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantially enacted at the balance sheet date. The impact on the account of changes in the deferred tax assets and liabilities has also been recognized in the statement of comprehensive income as per IAS-12: "Income Taxes".

## 2.12 Revenue Recognition

In accordance with the provisions of the IFRS-15: "Revenue from Contracts with Customers"; revenue from contracts with customers represents the amount that reflects the considerations to which entity expects to be entitled in exchange for goods supplied and service provided to customers during the year. Revenue from contracts with customers is recognized in the statement of profit or loss and other comprehensive income when the performance obligation (supply of promised goods and services) is satisfied. Performance obligation is satisfied at a point in time when customer obtains the control of goods and services. Revenue has been recognized at the time of invoice made for the services rendered by the company.

### Interest income

The interest income is recognized on accrual basis as agreed terms and conditions with the banks.

### Non operating income

Non operating income are recognized at the time of receive of money from other purpose than the normal course of business of the Company.

## 2.13 Earnings Per Share (EPS)

The Company calculates Earnings Per Share (EPS) in accordance with IAS -33 "Earnings Per Share", which has been shown on the face of the statement of comprehensive income. This has been calculated by dividing the basic earnings by the number of ordinary shares outstanding during the year.

## 2.14 Statement of Cash Flows

Statement of Cash Flows is prepared principally in accordance with IAS -7 "Statement of Cash Flows" and the cash flow from the operating activities have been presented under the direct method as prescribed by the Securities and Exchange Rules 1987 and considering the provision of Paragraph 19 of IAS -7 which provides that enterprise are encouraged to report "Cash Flow from the Operating Activities using the direct Method".

## 2.15 Additional information on Financial Statements:

### Compliance with International Financial Reporting Standards (IFRSs)

The financial statements have been prepared in compliance with requirements of IFRSs adopted by the Institute of Chartered Accountants of Bangladesh (ICAB).

## 2.16 Foreign Exchange Earned and Payment

During the period the Company has not earned or made payment any amount of foreign currency.

## 2.17 Provisions, Contingent Liabilities and Contingent Assets (IAS-37)

There are certain pending tax claims made against the Company, which will be settled through the legal process in due course. These are being vigorously defended by the company. The management has not considered it necessary at the reporting date to make provisions in the financial statements in respect of any of these claims.

Accounting Year	Assessment Year	Tax Declared	Assessment by Tribunal	Tax paid	Tax Liability/ Claimed Amount	Present Status
2012-2013	2013-2014	13,623,217	12,843,912	13,723,217	(879,305)	Case is Pending at High court
2013-2014	2014-2015	11,669,566	15,188,234	12,879,566	2,308,668	Case is Pending at High court
2014-2015	2015-2016	11,473,176	12,616,428	11,773,176	843,252	Case is Pending at High court

2015-2016	2016-2017	10,372,742	12,904,058	11,482,742	1,421,316	Case is Pending at High court
2016-2017	2017-2018	13,918,465	14,450,494	14,433,465	17,029	Case is Pending at High court
2017-2018	2018-2019	8,675,427	8,893,836	9,747,897	(854,061)	As per Assessment order
2018-2019	2019-2020	11,453,108	-	11,453,108	-	Return Submitted but Assessment not yet done
2019-2020	2020-2021	3,678,790	19,234,888	8,929,484	10,305,404	Case is Pending at Commissioner Appeal
2020-2021	2021-2022	13,632,068	-	11,246,630	2,385,438	Return Submitted but Assessment not yet done
<b>Total</b>		<b>98,496,559</b>	<b>96,131,850</b>	<b>105,669,285</b>	<b>15,547,741</b>	

### 2.18 Impairment of Assets (IAS-36)

No facts and circumstances indicate that the company's assets may be impaired. Hence, no evaluation of recoverability of assets was performed.

### 2.19 Employee Benefits (IAS-19)

The Company provides short term employee benefits to its eligible employees in the form of incentive which charged as revenue expenditure in the period to which the incentive relates.

### 2.20 Workers' Profit Participation and Welfare Fund:

The Company recognizes a provision for Workers' Profit Participation Fund @ 5% of net profit before Taxes in accordance with Bangladesh Labour Law 2006.

	As at September, 30 2022	As at June, 30 2022
<b>3. Property, Plant &amp; Equipment:</b>		
<b>Cost/Revaluation:</b>		
Land	760,247	760,247
Building	254,281	254,281
Equipments	168,194	162,090
Furniture & Fixture	29,543	25,205
Lift	13,870	13,870
Generator	7,630	7,630
Medical Oxygen System	29,055	28,995
Others	45,568	44,150
	<b>1,308,388</b>	<b>1,296,468</b>
Less: Accumulated Depreciation	323,747	318,348
Written Down Value	<b>984,641</b>	<b>978,120</b>
<b>4.Right of Use Assets</b>		
Cost	3,992	4,790
Less: Amortisation	399	798
	<b>3,593</b>	<b>3,992</b>
<b>5. Investment in Associate:</b>		
Opening Balance	5,829	5,794
Share of income / (loss) of Associate (note.24)	15	35
	<b>5,844</b>	<b>5,829</b>

Figure in Taka"000"

Share of income of Associate has been shown on the basis of unaudited report of the Imaging services Ltd. (Associate company) for the 1st quarter ended september 30 , 2022 in accordance with IAS-28.



As at  
September, 30  
2022

As at  
June, 30  
2022

Figure in Taka"000"

**6. Inventories:**

Medical Services	3,251	3,361
Diagnostics	1,871	2,656
Pharmacy	15,258	14,394
	<u>20,380</u>	<u>20,411</u>

**7. Trade Receivable:**

Receivable from Indoor Patient	6,703	6,573
Receivable from Outdoor Patient	368	223
Receivable from Institution	2,806	2,972
Rent Receivable	323	239
Receivable from FDR Interest	350	315
	<u>10,550</u>	<u>10,322</u>

**8. Advance, Deposits & Prepayments :**

Advance for Work & others	3,063	5,042
Advance for Capital Item	7,755	8,605
Security Money & Deposit	1,472	1,472
Prepayments	6,932	3,132
	<u>19,222</u>	<u>18,251</u>

**9. Advance Income Tax**

Opening Balance	15,787	17,743
Add: Paid during the year	115	6,282
	<u>15,902</u>	<u>24,025</u>
Less: Adjusted during the year	-	8,238
<b>Closing Balance</b>	<u>15,902</u>	<u>15,787</u>

**10. Cash & Cash Equivalents :**

Cash in hand	1,237	852
Union Bank FDR	30,000	30,000
Cash at bank	37,003	38,610
	<u>68,240</u>	<u>69,462</u>

**11. Issued, Subscribed and Paid up Capital:**

1,88,75,236 shares @ Tk. 10.00 each	<u>188,752</u>	<u>188,752</u>
-------------------------------------	----------------	----------------

**12. Retained Earnings**

Opening Balance	140,203	145,705
Less: Dividend Paid	-	18,875
	<u>140,203</u>	<u>126,830</u>
Add: Total Comprehensive Income for the year	2,742	16,292
	<u>142,945</u>	<u>143,122</u>
Less: Transferred to Dividend Equalisation Fund	-	2,919
	<u>142,945</u>	<u>140,203</u>

**13. Dividend Equalisation Fund:**

Opening	2,919	-
Add: Addition	-	2,919
<b>Closing</b>	<u>2,919</u>	<u>2,919</u>

As per decision of 188th meeting of the Board of Directors held on July 18, 2020 , 5% of net profit has been transferred to Dividend Equalisation fund.

**14. Revaluation Reserve**

Opening Balance	636,826	636,826
	<u>636,826</u>	<u>636,826</u>

**15. Deferred Tax Liabilities**

Opening Balance	43,323	40,433
Add: Provision made during the year for temporary difference(Note:15.01)	40	2,890
	<u>43,364</u>	<u>43,323</u>

**15.01 Deferred tax liability is arrived at as follows :**

**i. Deferred tax on PPE**

Carrying amount (Accounting base)	320,023	313,502
Carrying amount (Tax base)	250,819	243,948
Taxable/(deductible) temporary difference	69,204	69,554
Permanent differences	-	915
Net Taxable/(deductible) temporary difference	<u>69,204</u>	<u>68,639</u>
<b>Deferred tax Liability/(Assets) @ 22.50%</b>	<u>15,571</u>	<u>15,444</u>

	As at September, 30 2022	As at June, 30 2022
Figure in Taka"000"		
ii. <b>Deferred tax on Right of Use Assets</b>		
Carrying amount (Accounting base)	3,593	3,992
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	3,593	3,992
<b>Deferred tax Liability/(Assets) @ 22.50%</b>	<b>808</b>	<b>898</b>
iii. <b>Deferred tax on Lease Liabilities</b>		
Carrying amount (Accounting base)	2,264	2,264
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	(2,264)	(2,264)
<b>Deferred tax Liability/(Assets) @ 22.50%</b>	<b>(509)</b>	<b>(509)</b>
iv. <b>Deferred tax on share of profit on Investments</b>		
Carrying amount (Accounting base)	5,844	5,829
Carrying amount (Tax base)	7,335	7,335
Taxable/(deductible) temporary difference	(1,491)	(1,506)
<b>Deferred tax Liability/(Assets) @ 20%</b>	<b>(298)</b>	<b>(301)</b>
v. <b>Deferred tax on revaluation of property, plant and equipment:</b>		
Carrying amount (Accounting base)	694,800	694,800
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	694,800	694,800
<b>Deferred tax Liability/(Assets) @ 4%</b>	<b>27,792</b>	<b>27,792</b>
<b>Total deferred tax liability as on Sept 30, 2022</b>	<b>43,364</b>	<b>43,323</b>
<b>Movement of Deferred Tax on PL Items</b>		
<b>Opening Deferred Tax Liability</b>	<b>15,531</b>	<b>12,641</b>
Expense/(Income) during the year	40	2,890
<b>Closing Deferred Tax Liability</b>	<b>15,572</b>	<b>15,531</b>
<b>16 Lease Liability</b>		
Opening Balance	4,079	-
Addition during the year	-	4,790
Finance costs during the year	86	196
Payments during the year	(454)	(907)
<b>Closing Liability</b>	<b>3,711</b>	<b>4,079</b>
<b>16.01 Lease Liability</b>		
Lease Liability-Current	1,447	1,815
Lease Liability-Non Current	2,264	2,264
	<b>3,711</b>	<b>4,079</b>
<b>17. Long Term Loan</b>		
<b>a. Principle Amount</b>		
Opening Balance	55,000	55,000
Add: Addition during the year	-	-
	<b>55,000</b>	<b>55,000</b>
Less: Repayment	2,481	-
<b>Total</b>	<b>52,519</b>	<b>55,000</b>
<b>b. Interest Amount</b>		
Opening Balance	1,551	1,504
Add: Addition during the year	1,233	5,312
	<b>2,784</b>	<b>6,816</b>
Less: Repayment	2,784	5,265
<b>Total</b>	<b>-</b>	<b>1,551</b>
<b>Closing Balance</b>	<b>52,519</b>	<b>56,551</b>
Less: Long Term Loan (Current Portion)	17,028	21,060
<b>Total</b>	<b>35,491</b>	<b>35,491</b>
All fixed and floating assets are mortgaged against long term loan.		
<b>18. Trade Payable:</b>		
Advance Receipt from Undischarged Patient	3,743	1,682
Advance Receipt from MTB & Others	726	719
Current Liability for Expenses	718	657
Current Liabilities for Supply	13,041	8,705
Current Liabilities Construction	390	4,195
Workers profit participation fund (note 18.01)	14,955	14,770
	<b>33,573</b>	<b>30,728</b>

As at  
September, 30  
2022

As at  
June, 30  
2022

Figure in Taka"000"

**18.01. Workers profit participation fund :**

Opening Balance	14,770	12,347
Less: Paid During the year	-	214
	14,770	12,133
Add: Provision made during the year	185	1,217
Add: Interest Charged for the year	-	1,420
	<b>14,955</b>	<b>14,770</b>

**19. Long Term Loan (Current Portion)**

Closing Balance	<b>17,028</b>	<b>21,060</b>
-----------------	---------------	---------------

**20. Other Payables**

Suppliers & Others Vat	1596	434
Suppliers & Others Tax	951	310
Managing Directors Salary Tax	335	-
	<b>2,882</b>	<b>744</b>

**21. Provision & Accruals:**

Utility Bills	1,466	1,449
Salary & Allowance	8,049	7,284
Bad debt	106	-
Others	390	288
	<b>10,011</b>	<b>9,021</b>

**22. Provision for Income Taxes**

Opening Balance	7,856	13,948
Less: Adjusted during the year (Note-9)	-	8,238
	7,856	5,710
Less: Paid During the Year	-	3,009
	7,856	2,701
Add: Provision made during the year	915	5,155
	<b>8,771</b>	<b>7,856</b>

**23. Unclaimed Dividend**

Opening Balance	1,172	9,293
Add : Addition during the year	928	45
	2,100	9,338
Less: Capital Market Stabilization Fund	-	8,165
Less: Paid during the year	-	1
	<b>2,100</b>	<b>1,172</b>

The Above amount of Tk.11,71,573 has been unclaimed for the financial year 2018-2019. As per BSEC Directive No. BSEC/CMRRCD/2021-386/03 dt.January 14, 2021 the amount shall be payable to CMFS as soon as the expiry of 3 years. Hence the amount shall be payable to CMSF on 30th December, 2022.

**24. Share of Profit / (loss) of Associate :**

Net profit/ (loss) of Associate company	33	78
Share of Profit/ (loss) of Associate company (45% of Tk. 33 )	<b>15</b>	<b>35</b>

September, 30  
2022

September, 30  
2021

Figure in Taka"000"

**25. Revenue**

Medical Services	36,469	55,351
Diagnostic	22,139	27,721
Pharmacy	24,323	36,858
	<b>82,931</b>	<b>119,930</b>

**26. Direct Expenses:**

Medical Services	7,245	9,325
Diagnostic	8,684	11,597
Pharmacy	17,714	26,433
	<b>33,643</b>	<b>47,355</b>



	September, 30 2022	September, 30 2021
Figure in Taka"000"		
<b>27. Administrative Expenses:</b>		
Salary & Allowance	24,988	24,817
Managing Director's Salary	2,055	1,259
Utility Bills	4,881	4,647
Repair	1,541	1,281
Depreciation	5,400	4,876
Depreciation on Right of Use Assets	399	-
Printing	302	427
Bad debt	106	669
Others	6,374	7,181
	<b>46,046</b>	<b>45,157</b>
<b>28. Financial Expenses</b>		
Interest on Term Loan	1,233	-
Interest on Lease Liability	86	-
	<b>1,319</b>	<b>-</b>
<b>29. Non Operating Income</b>		
Rent Received	982	615
FDR Interest	560	739
Referral Income	164	-
Others	239	120
	<b>1,945</b>	<b>1,474</b>
<b>30. Current year's Tax</b>	<b>915</b>	<b>6,276</b>
<b>i. Regular Tax</b>		
Net profit before tax as per profit & loss Account	3,697	26,305
Less: Profit/(Loss) from Investments	15	28
	<b>3,683</b>	<b>26,277</b>
<b>Add: Items of charges to be considered separately:</b>		
Accounting depreciation	5,400	4,876
Depreciation on RoU Assets	399	-
Finance Cost on Lease Liabilities	86	-
	<b>5,885</b>	<b>4,876</b>
<b>Less: Admissible items:</b>		
Payments for Leases	454	-
Tax depreciation	5,049	3,258
	<b>5,503</b>	<b>3,258</b>
<b>Total business income during the year</b>	<b>4,065</b>	<b>27,895</b>
Regular Tax on business income @ 22.5%	915	6,276
	<b>915</b>	<b>6,276</b>

**31. Special disclosure as per notification No. BSEC/CMRRCD/2006-158/208/Admin/81 is as under:**

	As at September, 30 2022	As at June, 30 2022
Figure in Taka"000"		
<b>a ) Detailed break-up of shareholders equity:</b>		
Share Capital (note- a.01)	188,752	188,752
Retained Earnings (note- a.02)	142,945	140,203
Revaluation Reserve (note- a.03)	636,826	636,826
Dividend Equalisation Fund	2,919	2,919
<b>Total Equity</b>	<b>971,442</b>	<b>968,700</b>

**a.01 , Paid-up capital:**

Type of Share	No. of Shares	Face value	Issu Date	Figure in Taka"000"	
Ordinary Share	6,000	10.00	10/11/1997	60,000	60,000
Bonus Share	600	10.00	23/04/2005	6,000	6,000
Bonus Share	990	10.00	26/01/2010	9,900	9,900
Bonus Share	1,214	10.00	08/02/2012	12,140	12,140
Bonus Share	1,584	10.00	24/01/2013	15,844	15,844
Bonus Share	3,117	10.00	26/01/2014	31,170	31,170
Bonus Share	1,351	10.00	07/01/2015	13,510	13,510
Bonus Share	1,486	10.00	26/12/2016	14,860	14,860
Bonus Share	1,634	10.00	28/12/2017	16,340	16,340
Bonus Share	899	10.00	05/01/2020	8,988	8,988
<b>Total: 1,88,75,236 shares @ Tk. 10.00 each</b>				<b>188,752</b>	<b>188,752</b>

**a.02 , Retained Earnings**

Opening Balance	140,203	145,705
Less: Dividend Paid	-	18,875
	140,203	126,830
Add: Total Comprehensive Income for the year	2,742	16,292
	142,945	143,122
Less: Transferred to Dividend Equalisation Fund	-	2,919
Retained Earnings	<b>142,945</b>	<b>140,203</b>

As at  
September, 30  
2022

As at  
June, 30  
2022

Figure in Taka"000"

**a.03. Revaluation Reserve****636,826****636,826****b) Net Asset Value Per Share (NAV)**

Total Assets	1,128,372	1,122,174
Less Total liabilities :	156,930	153,474
Non Current Liabilities	81,119	81,078
Current Liabilities	75,811	72,396
Net Assets:	<b>971,441</b>	<b>968,700</b>
Number of outstanding shares at the year end	18,875	18,875
Net Asset Value Per Share (NAV)	<b>51.47</b>	<b>51.32</b>

September, 30  
2022

September, 30  
2021

Figure in Taka"000"

**c) Basic and diluted Earnings Per Share:****Basic Earning Per Share:**

Profit Attributable to ordinary shareholders	2,742	20,392
Number of outstanding shares at the year end	18,875	18,875
Basic Earning per Share (EPS)	<b>0.15</b>	<b>1.08</b>

**Diluted Earning Per Share:**

Diluted EPS is determined by adjusting the Profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary share during the relevant period.

**d) Net operating cash flows per share (NOCFPS)**

Net Cash from Operating Activities	17,466	29,589
Number of outstanding shares at the year end	18,875	18,875
Net operating cash flows per share (NOCFPS)	<b>0.93</b>	<b>1.57</b>



**e) Reconciliation of Net profit with Cash Flows from Operating Activities**

For the 1st Quarter ended September 30, 2022


Particulars	September, 30 2022	September, 30 2021
	Figure in Taka "000"	
Profit Before Tax	3,697	26,305
Depreciation	5,799	4,876
Bad debt	106	669
(Gain) / Loss on Disposal	-	-
FDR Interest	(560)	(739)
Investment Income (Share of (Profit) /Loss of Associates)	(15)	(28)
Financial Charges	1,319	1,300
Payment for lease	(454)	-
(Increase)/Decrease in Inventories	31	(665)
(Increase)/Decrease in Trade and other receivable	(193)	(3,999)
(Increase)/Decrease in Advance, Deposits & Prepayment	(1,821)	(1,418)
Increase/(Decrease) in Trade Payable	6,465	2,404
Increase/(Decrease) in other Payable	2,138	1,488
Increase/(Decrease) in Provision & accruals	884	697
Increase/(Decrease) in WPPF	185	1,315
Cash Flows from operation	17,581	32,205
Tax Paid	(115)	(2,616)
	17,466	29,589

**32. Related Party Disclosures (IAS-24):**

as on 30th September 2022 ( Figure in Taka "000")

SL.No	Particulars	Nature of Relation	Basis of transactions	Total Transaction Value	Outstanding
1.00	Nurse Hostel	Mrs. Latifa Haroon, W/O Dr.A B M Haroon	Rent paid as per contract	485	-
2.00	The Imaging Services Ltd.	Associate company	Rent received as per contract	248	84
3.00	Purabi General Insurance Company Limited	Common director	Insurance Premium paid as per contract	71	-
4.00	M.H. Samorita Hospital & Medical College	Common director	Pathology Test as per negotiation	1,191	1,191

  
CFO

  
Company Secretary

  
Managing Director

  
Director

  
Chairman